Ashish M. Kamat, MD, MBBS
@UroDocAsh
Followers
12K
Following
21K
Media
1K
Statuses
10K
Endowed Professor, Surgeon, Former Fellowship Director @MDAndersonNews | President, IBCG | Assoc Editor @EurUrolOncol | Views my own
Houston, TX
Joined March 2010
After a successful 3rd @IBCG_BladderCA Retreat'25, was great to recap with @UroDocAsh @pjhensley11 @UrogerliMD all the work that went behind the scenes for the topics, goals of the meeting & the central role of patient advocates.
Multidisciplinary and global perspectives on #BladderCancer management. @shilpaonc, @pjhensley11 & @UrogerliMD join @UroDocAsh to dissect the #IBCG2025 retreat's foundational principles and collaborative methodology. #WatchNow > https://t.co/7CYnrx5ETH
@IBCG_BladderCA #IBCG25
0
5
24
The Department of Urology @MDAndersonNews is hosting an @UroOnc open house. When: Thursday, Nov 20, 2025 at 07:00 PM Central Time (US and Canada) Register in advance for this webinar: https://t.co/eXDYD0fYmV
mdacc.zoom.us
Welcome! You are invited to join a webinar: MD Anderson Cancer Center - SUO Fellowship Open House. After registering, you will receive a confirmation email about joining the webinar.
2
3
12
📢 Excited to share the latest from our lab: we discovered a new synthetic-lethal vulnerability in cancer cells with APOBEC3A activity and its underlying mechanism 🔧🧩 -APOBEC3A induces DNA double-strand breaks🧬✂️🧬 - APOBEC3A shifts double-strand DNA break repair towards
10
46
155
Simposio @IBCG_BladderCA: Descifrando la categoría de riesgo intermedio en #CáncerVejiga con Dr. Ashish Kamat. Un grupo heterogéneo en diagnóstico y tratamientos #CongresoCentenarioSCHU
0
2
6
Mesa redonda sobre CVNMI: expertos nac. e internac. revisaron casos clínicos en los que abordaron distintas presentaciones del cáncer de vejiga. Además, compararon las experiencias en distintos centros. Aspecto destacado: opciones terapia intravesical. #CongresoCentenarioSCHU
1
3
4
Financial toxicity and economic burden for #BladderCancer patients. Parminder Singh, MD @MayoClinic joins @UroDocAsh @MDAndersonNews discussing the costs associated with a bladder cancer diagnosis and how bladder cancer has become one of the most expensive cancers to treat, with
1
4
9
PCF Scientific Retreat: @PCFnews @PCF_Science @urotoday CEO Gina Carithers giving the CEO Address Continued incredible growth for @urotoday in 2025 (Jan-Sept): 📢7.5 mill page views (⬆️ 21% '24) 📢4.42 mill site visitors (⬆️ 36% '24) Up to 30K @X followers (⬆️ 22% '24) 👏👏👏
0
5
18
Biomarkers for guiding #BladderCancer treatment decisions. @AndreaNecchi @SanRaffaeleMI and @UroDocAsh @MDAndersonNews discuss biomarkers in bladder cancer management. Dr. Necchi reviews immunotherapy biomarkers including tumor mutational burden (TMB), emphasizing its continuous
0
5
11
Best wishes, Mr. President - you couldn’t be in better hands than with @NehaVapiwala
@JoeBiden
Congratulations to President @JoeBiden for finishing RT under the care of @ASTRO_org President @NehaVapiwala
@PennMedicine #radonc
0
5
52
Tremendous presentation by @tompowles1 #ESMO25 @myESMO on IMvigor011 born from the most imp neg trial IMvigor010 in bladderca. Practice changing data for the 1st time using ctDNA for tx intervention in adjuvant setting in MIBC. @DrChoueiri @MyriamChalabi @montypal @Uromigos
0
19
46
Very insightful discussion of IMvigor011 by @ResearchWyatt @myESMO #ESMO25 Strongest evidence to date for ctDNA to guide adjuavnt IO treatment in MIBC. @tompowles1 @Uromigos @DrChoueiri @montypal
1
9
37
Disitamab vedotin + toripalimab vs chemotherapy in first-line locally advanced or metastatic #UrothelialCarcinoma with HER2-expression. Presented by Jun Guo, MD. @RKSayyid @UAUrology > https://t.co/fLVuHbAHK7
@myESMO @UroDocAsh
0
5
7
Could not Miss the challenge of expert session so nicely chaired by our own @BrigidaMaiorano with Charles Nguyen. Second Line therapy of urothelial cancer has become quite complicated! @SanRaffaeleMI @MyUniSR @cityofhope @montypal @neerajaiims @SpiessPhilippe @UroDocAsh
1
8
24
Evaluating chemotherapy de-escalation in first-line #UrothelialCarcinoma: #DISCUS Trial. @drenriquegrande joins @UroDocAsh in this conversation on the DISCUS trial, a phase II study comparing three versus six cycles of platinum-based chemotherapy before avelumab maintenance in
1
2
4
Health-related quality of life outcomes from the #NIAGARA trial in #BladderCancer. @MichvdHeijden @hetAVL joins @UroDocAsh @MDAndersonNews discussing the NIAGARA trial health-related quality of life outcomes, demonstrating perioperative durvalumab added to neoadjuvant
1
3
7
Sure hope so! - but we’ve been down this road before, and unfortunately patients paid the price when enthusiasm outpaced the evidence. A pCR is only part of the story; the real question is what happens when patients stop systemic therapy and return to “real life” outside a trial
The countdown for radical cystectomy being an obsolete surgery is on.....5 years? 🧐🧐
2
14
62
1/2 KN905 Enfortumab Vedotin + Pembro continues to transform bladder cancer in spectacle fashion. In cisplatin ineligible operable disease it beats cystectomy with EFS HR 0.4, OS HR 0.5. pCR of 57% is much ⬆️ than anything before #ESMO25 pCR> 50% questions unselected surgery
5
137
341
Perioperative enfortumab vedotin + pembrolizumab in participants with muscle-invasive bladder cancer who are cisplatin-ineligible: the phase 3 KEYNOTE-905 study. Presented by Christof Vulsteke, MD, PhD. #ESMO25 written coverage by @chavarriagaj @UofT > https://t.co/PK8psJZ5ow
1
13
20
@TiansterZhang @DrRosenbergMSK @myESMO @OncoAlert @DrChoueiri @montypal @PGrivasMDPhD @shilpaonc @ERPlimackMD @apolo_andrea @neerajaiims @QianJanieQin Full written coverage of @DrRosenbergMSK’s #ESMO25 discussant presentation on perioperative EV + pembrolizumab in cisplatin-ineligible MIBC — now available on @UroToday 👇 written by @chavarriagaj @myESMO @UroDocAsh 📝
0
7
11